GlassScriptPhysician profile
Farhan S Imran
NPI 1518133875
$428.56
in general payments reported to CMS, 2019-2025
13 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.19 · 2020: $35.23 · 2021: $34.00 · 2022: $19.86 · 2023: $17.88 · 2024: $95.12 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201 · Education: $85.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.05 |
| Education | $85.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.09 | 2022-2025 | Reblozyl |
| Janssen Biotech, INC. | $82.24 | 2019-2024 | Rybrevant |
| Pfizer INC. | $61.30 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $42.47 | 2019-2025 | Tagrisso |
| Gilead Sciences, INC. | $34.44 | 2021-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $24.25 | 2025 | Keytruda, Lynparza |
| Sumitomo Pharma America, INC. | $23.93 | 2024 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $23.39 | 2024 | Fruzaqla |
| Pharmaessentia USA Corporation | $17.88 | 2023 | Besremi |
| Rigel Pharmaceuticals, INC. | $17.45 | 2020 | |
| Amgen INC. | $13.12 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.